Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden

References

• Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):1–8. doi: 10.1016/j.jacc.2019.04.003.
   PubMed Web of Science ®Google Scholar
• Saito Y, Nakamura K, Ito H. Molecular mechanisms of cardiac amyloidosis. Int J Mol Sci. 2021;23(1):25.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med. 2018;18(Suppl 2):S30–S35. doi: 10.7861/clinmedicine.18-2-s30.
   PubMed Web of Science ®Google Scholar
• Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):198. doi: 10.1186/s12875-020-01252-4.
   PubMed Web of Science ®Google Scholar
• Nativi-Nicolau J, Judge DP, Hoffman JE, et al. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021;8(5):3875–3884. doi: 10.1002/ehf2.13541.
   PubMed Web of Science ®Google Scholar
• Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. doi: 10.1161/CIRCULATIONAHA.118.038169.
   PubMed Web of Science ®Google Scholar
• Aus Dem Siepen F, Hein S, Prestel S, et al. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol. 2019;108(12):1324–1330. doi: 10.1007/s00392-019-01467-1.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806. doi: 10.1093/eurheartj/ehx589.
   PubMed Web of Science ®Google Scholar
• Grogan M, Scott CG, Kyle RA, et al. Natural history of Wild-Type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–1020. doi: 10.1016/j.jacc.2016.06.033.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in Northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994;31(5):351–354. doi: 10.1136/jmg.31.5.351.
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829–837. doi: 10.1002/mus.26034.
   PubMed Web of Science ®Google Scholar
• Bajwa F, O'Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022;27(5):1471–1484. doi: 10.1007/s10741-021-10162-1.
   PubMed Web of Science ®Google Scholar
• Lauppe RE, Liseth Hansen J, Gerdesköld C, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. Open Heart. 2021;8(2):e001755. doi: 10.1136/openhrt-2021-001755.
   PubMed Web of Science ®Google Scholar
• Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med. 2022;9:863179. doi: 10.3389/fcvm.2022.863179.
   PubMed Web of Science ®Google Scholar
• Lindmark K, Pilebro B, Sundström T, et al. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021;8(1):745–749. doi: 10.1002/ehf2.13110.
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Large S, Bhambri R, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review. Cardiol Ther. 2021;10(1):141–159. doi: 10.1007/s40119-021-00219-5.
   PubMed Web of Science ®Google Scholar
• Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568. doi: 10.1093/eurheartj/ehab072.
   PubMed Web of Science ®Google Scholar
• Benbrahim M, Norman K, Sanchorawala V, et al. A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis. J Cardiovasc Pharmacol. 2021;77(5):544–548. doi: 10.1097/FJC.0000000000001004.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169–1186. doi: 10.1002/ejhf.1531.
   PubMed Web of Science ®Google Scholar
• Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement From the American heart association. Circulation. 2020;142(1):e7–e22. doi: 10.1161/CIR.0000000000000792.
   PubMed Web of Science ®Google Scholar
• Lauppe R, Liseth Hansen J, Fornwall A, et al. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022;9(3):1636–1642. doi: 10.1002/ehf2.13913.
   PubMed Web of Science ®Google Scholar
• Pilgaard T, Pedersen MH, Poulsen SH. Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark. J Med Econ. 2020;23(10):1084–1091. doi: 10.1080/13696998.2020.1789866.
   PubMed Web of Science ®Google Scholar
• Hjalte F, Norlin J, Alverbäck-Labberton L, et al. EE434 health care resource use and costs in transthyretin amyloid cardiomyopathy-A swedish medical record review study. Value in Health. 2022;25(12):S141. doi: 10.1016/j.jval.2022.09.680.
   Web of Science ®Google Scholar
• Stålhammar J, Stern L, Linder R, et al. The burden of preserved ejection fraction heart failure in a real-world swedish patient population. J Med Econ. 2014;17(1):43–51. doi: 10.3111/13696998.2013.848808.
   PubMedGoogle Scholar
• Boman K, Lindmark K, Stålhammar J, et al. Healthcare resource utilisation and costs associated with a heart failure diagnosis: a retrospective, population-based cohort study in Sweden. BMJ Open. 2021;11(10):e053806. doi: 10.1136/bmjopen-2021-053806.
   PubMed Web of Science ®Google Scholar
• Alexander KM, Evangelisti A, Witteles RM. Emerging therapies for transthyretin cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2019;21(8):40.
   PubMedGoogle Scholar
• Eldhagen P, Lehtonen J, Gude E, et al. Health-related quality of life among transthyretin amyloid cardiomyopathy patients. ESC Heart Fail. 2023;10(3):1871–1882. doi: 10.1002/ehf2.14350.
   PubMed Web of Science ®Google Scholar
• Formiga F, García-Pavía P, Martín Sánchez FJ, et al. Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2021;11:1–7.
   Google Scholar